Attana to present scientific results at a conference for antibodies in clinical oncology on Cyprus June 18-20, 2018
One of the longest-running conferences in the field of monoclonal antibodies, the 35th Conference on Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells will include presentations by leading researchers on scientific and clinical aspects of monoclonal antibodies in clinical oncology. Attana will attend the conference as speaker. The presentation, “Efficient drug candidate selection using label-free cell-based biosensor” will be given by Dr. Diluka Peiris, Head of Attana´s UK operations.
During the conference, Dr. Peiris will present how the Attana technology has been applied and can be used in the development of new pharmaceuticals. Dr. Peiris will focus on Attana´s assays for investigating the effect of cell glycosylation on receptor accessibility in cancer. Dr Peiris will present findings that illustrate the importance of glycosylation profiles in modulating the responsiveness of cancer cells to treatments. Furthermore, these findings will highlight the benefits of performing cell-based assays. In addition to the scientific presentation program, the conference also has several sessions for discussions between conference participants. The purpose of these sessions is to share information and to establish new contacts and collaborations.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact email@example.com.